These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3118265)

  • 61. Treatment of iron overload in children and adolescents on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA
    Eur J Pediatr; 1990 Feb; 149(5):359-62. PubMed ID: 2311634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of desferrioxamine infusion on red blood cell aluminum.
    Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
    ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevention and treatment of aluminum overload in uremic patients: long-term results.
    Canavese C; Thea A; Pacitti A; Salomone M; Mangiarotti G; Segoloni G; Stratta P; Gurioli L; Constantini S; Giordini R
    Clin Nephrol; 1989 Apr; 31(4):169-74. PubMed ID: 2714022
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
    Anthone S; Ambrus CM; Kohli R; Min I; Anthone R; Stadler A; Stadler I; Vladutiu A
    J Am Soc Nephrol; 1995 Oct; 6(4):1271-7. PubMed ID: 8589296
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 66. Low-dose desferrioxamine test for the diagnosis of aluminium-related bone disease in patients on regular haemodialysis.
    Yaqoob M; Ahmad R; Roberts N; Helliwell T
    Nephrol Dial Transplant; 1991; 6(7):484-6. PubMed ID: 1922909
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
    Huang JY; Wu MS; Wu CH
    Ren Fail; 2001 Nov; 23(6):789-95. PubMed ID: 11777318
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Anemia of chronically hemodialyzed patients].
    Csata S; Koller O; Szendi L; Légrádi J
    Acta Chir Acad Sci Hung; 1975; 16(1):97-103. PubMed ID: 1154963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine.
    de la Serna FJ; Praga M; Gilsanz F; Rodicio JL; Ruilope LM; Alcazar JM
    Lancet; 1988 May; 1(8593):1009-11. PubMed ID: 2896866
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
    Roxe DM; Krumlovsky FA; Del Greco F; Fitzsimons E
    Int J Artif Organs; 1990 Apr; 13(4):211-7. PubMed ID: 2115505
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnosis and treatment of iron overload in paediatric patients on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA; van Dijken PJ
    Pediatr Nephrol; 1988 Jul; 2(3):303-8. PubMed ID: 3153030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.
    Stivelman J; Schulman G; Fosburg M; Lazarus JM; Hakim RM
    Kidney Int; 1989 Dec; 36(6):1125-32. PubMed ID: 2601259
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis.
    Alfurayh O; Sobh M; Barri Y; Qunibi W; Taher S
    Nephrol Dial Transplant; 1992; 7(9):939-43. PubMed ID: 1328942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
    Altmann P; Plowman D; Marsh F; Cunningham J
    Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
    Canavese C; Gurioli L; D'Amicone M; Cardelli R; Caligaris F; Bongiorno P; Arnaud A; Mattiello G; Marchiori M
    Nephron; 1992; 60(4):411-7. PubMed ID: 1584315
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Desferrioxamine induced aluminium removal in haemodialysis.
    Bonal J; Montoliu J; Löpez Pedret J; Bergadä E; Andrew L; Bachs M; Revert L
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():366-70. PubMed ID: 3991524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.